You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
上海醫藥(601607.SH):奧美拉唑碳酸氫鈉幹混懸劑(Ⅱ)獲得批准生產
格隆匯 03-13 20:15

格隆匯3月13日丨上海醫藥(601607.SH)公佈,公司下屬全資子公司上海上藥信誼藥廠有限公司(稱“上藥信誼”)的奧美拉唑碳酸氫鈉幹混懸劑(Ⅱ)(稱“該藥品”)收到國家藥品監督管理局頒發的《藥品註冊證書》(證書編號:2025S00589),該藥品獲得批准生產。奧美拉唑碳酸氫鈉幹混懸劑(Ⅱ)(每袋含奧美拉唑40mg和碳酸氫鈉1680mg)主要用於活動性良性胃潰瘍的治療(4-8周)。

根據國家相關政策,按新註冊分類獲批仿製藥的品種在醫保支付及醫療機構採購等領域將獲得更大的支持力度。因此上藥信誼的奧美拉唑碳酸氫鈉幹混懸劑(Ⅱ)獲得批准生產,有利於擴大該藥品的市場份額,提升市場競爭力,同時為公司後續產品開展仿製藥申報積累了寶貴的經驗。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account